Web Desc
Asthma: New Discoveries and Therapies in the Age of COVID - VIRTUAL CONTENT AVAILABLE ON DEMAND
Organizer(s): Michael J. Holtzman, Philippa C. Marrack, Anne I. Sperling and Prescott G. Woodruff
Date: December 01 - 02, 2020
Location: Virtual at your computer. Recorded presentation content is available On Demand.
Sponsored by Ionis Pharmaceuticals, Inc.
For important information on the coronavirus, please click here
Summary of Meeting:
Asthma and related diseases in the form of COPD and asthma-COPD are a remarkably common, affecting over 50 million patients in the US alone. Moreover, this disease spectrum overlaps with inflammatory lung disease driven by respiratory viral infection, including COVID-19. In the case of asthma, the pathology is thought to arise from an aberrant type 2 immune response, but the cellular and molecular mechanisms of this response require more precise definition, including any contribution from non-type 2 immune mechanisms. Clinical trials based on these concepts have revealed both successes and also some unforeseen failures that need to be addressed and included in the framework of respiratory viruses in general and SARS-CoV-2 in particular. This Keystone Symposia conference on asthma will highlight the most recent basic science breakthroughs in the pathogenesis of asthma and related inflammatory airway diseases and focus on the development of new therapeutics for asthma and related progressive respiratory disease. In addition, the program will review these discoveries in the context of new therapeutic directions, including the context of emerging information about COVID-19. The program has been designed to emphasize to identify, validate, and translate new disease targets into new therapeutics. The topic is timely and urgent given the recent mechanistic insights into inflammatory airway disease, the current maturation of new biological therapies for this type of disease, and the overlap of this information with progressive lung disease after respiratory viral infections, including COVID-19.
Global Health Travel Award Deadline: November 17 2020
Scholarship Deadline: October 17 2020
Abstract Deadline: November 3 2020
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Ionis Pharmaceuticals, Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Heart, Lung, and Blood Institute (NHLBI)
Grant No. 1 R13 HL152474-01
Funding for this conference was made possible (in part) by 1 R13 HL152474-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Tuesday, December 01 | 8:00AM - 8:05AM
Welcoming Remarks (8am Denver/Mountain Time Start)

Speaker 1 of 1
Michael J. Holtzman, Washington University in St. Louis, USA

Tuesday, December 01 | 8:05AM - 11:00AM
Upstream and Downstream Ways to Stop Airway Disease (8:05am
Denver/Mountain Time Start)


Speaker 1 of 9
* Philippa C. Marrack, HHMI/National Jewish Health, USA

Tuesday, December 01 | 8:05AM - 11:00AM
Upstream and Downstream Ways to Stop Airway Disease (8:05am
Denver/Mountain Time Start)


Speaker 2 of 9
Karen Affleck, GlaxoSmithKline, UK
System-Based Approaches to Learn from Asthma Remissions

Tuesday, December 01 | 8:05AM - 11:00AM
Upstream and Downstream Ways to Stop Airway Disease (8:05am
Denver/Mountain Time Start)


Speaker 3 of 9
* Michael J. Holtzman, Washington University in St. Louis, USA
Correcting Post-Viral Disease (including COVID and Its Cousins)

Tuesday, December 01 | 8:05AM - 11:00AM
Upstream and Downstream Ways to Stop Airway Disease (8:05am
Denver/Mountain Time Start)


Speaker 4 of 9
Jonathan Corren, University of California, Los Angeles, USA
Progress with TSLP Therapeutics in Lung Disease

Tuesday, December 01 | 8:05AM - 11:00AM
Upstream and Downstream Ways to Stop Airway Disease (8:05am
Denver/Mountain Time Start)



Coffee Break

Tuesday, December 01 | 8:05AM - 11:00AM
Upstream and Downstream Ways to Stop Airway Disease (8:05am
Denver/Mountain Time Start)


Speaker 6 of 9
David B. Corry, Baylor College of Medicine, USA
Silencing Transcription Factors and Pathogens in Asthma and COVID-19: Two Biotechnology Vignettes

Tuesday, December 01 | 8:05AM - 11:00AM
Upstream and Downstream Ways to Stop Airway Disease (8:05am
Denver/Mountain Time Start)


Speaker 7 of 9
Joseph R. Arron, Genentech, Inc., USA
Navigating New Therapeutics for Asthma and COVID

Tuesday, December 01 | 8:05AM - 11:00AM
Upstream and Downstream Ways to Stop Airway Disease (8:05am
Denver/Mountain Time Start)


Speaker 8 of 9
Ivy Aneas-Swanson, University of Chicago, USA
Short Talk: Asthma-Associated Variants Induce IL33 Differential Expression through a Novel Regulatory Region

Tuesday, December 01 | 8:05AM - 11:00AM
Upstream and Downstream Ways to Stop Airway Disease (8:05am
Denver/Mountain Time Start)


Speaker 9 of 9
Gregg Duncan, University of Maryland, USA
Short Talk: Modeling Airway Dysfunction in Asthma Using Synthetic Mucus Biomaterials

Tuesday, December 01 | 12:30PM - 1:30PM
Career Roundtable (12:30pm Denver/Mountain Time Start)

Speaker 1 of 3
Prescott G. Woodruff, University of California, San Francisco, USA

Tuesday, December 01 | 12:30PM - 1:30PM
Career Roundtable (12:30pm Denver/Mountain Time Start)

Speaker 2 of 3
Karen Affleck, GlaxoSmithKline, UK

Tuesday, December 01 | 12:30PM - 1:30PM
Career Roundtable (12:30pm Denver/Mountain Time Start)

Speaker 3 of 3
Jeffrey Haspel, Washington University in St. Louis, USA

Tuesday, December 01 | 2:00PM - 5:00PM
New Controls in Asthma (2pm Denver/Mountain Time Start)

Speaker 1 of 8
Alexander Scheffold, Christian-Albrechts-Universität zu Kiel, Germany
The Role of Pre-Existing T Cell Memory and Cross-Reactivity for Allergic Inflammation and COVID-19

Tuesday, December 01 | 2:00PM - 5:00PM
New Controls in Asthma (2pm Denver/Mountain Time Start)

Speaker 2 of 8
* Anuradha Ray, University of Pittsburgh School of Medicine, USA
Type 1 Immune Response in Severe Asthma and Implications in COVID-19

Tuesday, December 01 | 2:00PM - 5:00PM
New Controls in Asthma (2pm Denver/Mountain Time Start)

Speaker 3 of 8
Vijay K. Kuchroo, Brigham and Women's Hospital, Harvard Medical School, USA
Neuro-Immune Interactions in Regulation of Type II Inflammation in Lung

Tuesday, December 01 | 2:00PM - 5:00PM
New Controls in Asthma (2pm Denver/Mountain Time Start)


Coffee Break

Tuesday, December 01 | 2:00PM - 5:00PM
New Controls in Asthma (2pm Denver/Mountain Time Start)

Speaker 5 of 8
* Anne I. Sperling, University of Chicago, USA
Dendritic Cells in Type 2 Inflammation

Tuesday, December 01 | 2:00PM - 5:00PM
New Controls in Asthma (2pm Denver/Mountain Time Start)

Speaker 6 of 8
Jeffrey Haspel, Washington University in St. Louis, USA
Circadian Approaches to Asthma and Viral Infection

Tuesday, December 01 | 2:00PM - 5:00PM
New Controls in Asthma (2pm Denver/Mountain Time Start)

Speaker 7 of 8
Carlos A. Castellanos, University of California, San Francisco, USA
Short Talk: Type 2 Immune Development Depends on MARCH1-mediated MHCII and CD86 Turnover in Lymph Node Resident Dendritic Cells

Tuesday, December 01 | 2:00PM - 5:00PM
New Controls in Asthma (2pm Denver/Mountain Time Start)

Speaker 8 of 8
Nathan R. Schoettler, University of Chicago, USA
Short Talk: CD4 Tissue Resident Memory T Cells Promote Inflammatory Pathways Associated with Asthma

Wednesday, December 02 | 8:00AM - 11:10AM
New Targets in Asthma (8am Denver/Mountain Time Start)

Speaker 1 of 9
* Rafeul Alam, National Jewish Health, USA
ILC2 Memory in Asthma

Wednesday, December 02 | 8:00AM - 11:10AM
New Targets in Asthma (8am Denver/Mountain Time Start)

Speaker 2 of 9
Maria Belvisi, Imperial College London / AstraZeneca, UK
Asthma Therapeutics: Now and Future Directions

Wednesday, December 02 | 8:00AM - 11:10AM
New Targets in Asthma (8am Denver/Mountain Time Start)

Speaker 3 of 9
Elliot Israel, Harvard Medical School/Brigham & Women's Hospital, USA
Tyrosine Kinase Inhibition in Asthma

Wednesday, December 02 | 8:00AM - 11:10AM
New Targets in Asthma (8am Denver/Mountain Time Start)

Speaker 4 of 9
* Jenny P.Y. Ting, University of North Carolina at Chapel Hill, USA
Innate Immunity in Host Defense and Asthma

Wednesday, December 02 | 8:00AM - 11:10AM
New Targets in Asthma (8am Denver/Mountain Time Start)


Coffee Break

Wednesday, December 02 | 8:00AM - 11:10AM
New Targets in Asthma (8am Denver/Mountain Time Start)

Speaker 6 of 9
Martijn C. Nawijn, University Medical Center Groningen, Netherlands
Lung Cell Maps for Asthma and COVID

Wednesday, December 02 | 8:00AM - 11:10AM
New Targets in Asthma (8am Denver/Mountain Time Start)

Speaker 7 of 9
Bart N. Lambrecht, VIB, Ghent University, Belgium
Innate Immunity and DCs in Response to Allergens and Virus Infection

Wednesday, December 02 | 8:00AM - 11:10AM
New Targets in Asthma (8am Denver/Mountain Time Start)

Speaker 8 of 9
Lorena Riol Blanco, Genentech, Inc., USA
Short Talk: A TRPA1 Inhibitor Suppresses Neurogenic Inflammation and Smooth Muscle Contraction for the Treatment of Asthma

Wednesday, December 02 | 8:00AM - 11:10AM
New Targets in Asthma (8am Denver/Mountain Time Start)

Speaker 9 of 9
Amanda Poholek, University of Pittsburgh, USA
Short Talk: Blimp-1 Is Essential for Allergen-Induced Asthma and Th2 Cell Development in the Lung

Wednesday, December 02 | 12:00PM - 2:00PM
Poster Session (12pm Denver/Mountain Time Start)


Wednesday, December 02 | 2:00PM - 5:00PM
New Systems for Personalized Therapeutics (2pm Denver/Mounta
in Time Start)


Speaker 1 of 8
* Clare M. Lloyd, Imperial College London, UK
Early Versus Later Life Lung Remodeling and Repair

Wednesday, December 02 | 2:00PM - 5:00PM
New Systems for Personalized Therapeutics (2pm Denver/Mounta
in Time Start)


Speaker 2 of 8
Parameswaran Nair, McMaster University, Canada
Biologicals for Severe Asthma during the COVID Pandemic

Wednesday, December 02 | 2:00PM - 5:00PM
New Systems for Personalized Therapeutics (2pm Denver/Mounta
in Time Start)


Speaker 3 of 8
Bali Pulendran, Stanford University School of Medicine, USA
Systems Immunology of Asthma and COVID-19

Wednesday, December 02 | 2:00PM - 5:00PM
New Systems for Personalized Therapeutics (2pm Denver/Mounta
in Time Start)



Coffee Break

Wednesday, December 02 | 2:00PM - 5:00PM
New Systems for Personalized Therapeutics (2pm Denver/Mounta
in Time Start)


Speaker 5 of 8
* Prescott G. Woodruff, University of California, San Francisco, USA
Biomarkers for Asthma and COVID-19

Wednesday, December 02 | 2:00PM - 5:00PM
New Systems for Personalized Therapeutics (2pm Denver/Mounta
in Time Start)


Speaker 6 of 8
Nora A. Barrett, Brigham and Women's Hospital, USA
Revisiting Airway Epithelial Remodeling in Type 2 Inflammation

Wednesday, December 02 | 2:00PM - 5:00PM
New Systems for Personalized Therapeutics (2pm Denver/Mounta
in Time Start)


Speaker 7 of 8
Kristina Johansson, University of California, San Francisco, USA
Short Talk: MicroRNA Regulation of Airway Mucus Production

Wednesday, December 02 | 2:00PM - 5:00PM
New Systems for Personalized Therapeutics (2pm Denver/Mounta
in Time Start)


Speaker 8 of 8
Katherine Cahill, Vanderbilt University, USA
Short Talk: Glucagon-like Peptide-1 Receptor Agonists Decrease Type-2 Biomarker in Asthma